CD8A and glioblastoma: Since cytoreductive therapy significantly impairs the immune system [37], the potential to induce strong CD8+ T-cell responses is particularly relevant for an antigen-based immunotherapeutic for GBM, where chemotherapy and radiotherapy remain the standard of care, and induced T cells must cross the blood–brain barrier to invade the immunologically “cold” tumour.